The latest strategic SWOT analysis and Q3 2024 financial results indicate a strong performance from Quest Diagnostics Inc (DGX). The company's revenue growth, especially from diagnostic test demand, has beaten estimates. Quest Diagnostics, awarded CDC contracts for H5 Avian Influenza and Oropouche Virus test development, continues to boost its service offerings. It has also been named a Best Place to Work for Disability Inclusion for the seventh consecutive year and reported new customer wins in Q3. It is expected to achieve further earnings growth in 2025. There are favorable sector trends and the stock was just upgraded to Outperform from Neutral at Baird and Strong-Buy at Baird R W. Recent acquisitions include select lab assets from Allina Health, OhioHealth's Lab Services and PathAI Diagnostics. The company has enhanced its patient-centered care with streamlined services, innovative testing, and a commitment to health equity in 2023. Quest Diagnostics has also demonstrated a promising 60% gain over the past five years, indicating strong share value for investors.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Fri, 25 Oct 2024 19:08:45 GMT - Rating 8 - Innovation 7 - Information 8 - Rumor 6
